Lakefront Biotherapeutics (LKFT) Receivables - Other (2015 - 2025)

Lakefront Biotherapeutics (LKFT) has reported Receivables - Other for 11 consecutive years, with $4.4 million the latest figure, recorded in Q4 2025.

• Quarterly Receivables - Other rose 69.0% year-over-year to $4.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.4 million (up 69.0% YoY) and the FY2025 annual result came in at $4.6 million, down 59.84% from the prior year.
• Receivables - Other grew to $4.4 million in Q4 2025 per LKFT's latest filing, from $2.6 million in the prior quarter.
• Over the last five years, Receivables - Other for LKFT reached as high as $14.3 million in Q4 2021 and fell as low as $2.6 million in Q4 2024.
• A 5-year average of $7.2 million and a median of $5.9 million in 2023 frame the typical range for Receivables - Other.
• Annual changes were most pronounced in 2024 — Receivables - Other sank 56.37% — and 2025, when it jumped 69.0%.
• Year by year, Receivables - Other stood at $14.3 million in 2021, then slumped by 37.48% to $9.0 million in 2022, then slumped by 34.01% to $5.9 million in 2023, then tumbled by 56.37% to $2.6 million in 2024, then surged by 69.0% to $4.4 million in 2025.
• According to Business Quant data, Receivables - Other over the past three periods registered $4.4 million, $2.6 million, and $5.9 million for Q4 2025, Q4 2024, and Q4 2023 respectively.